Recombinant versus plasma-derived factor IX in the treatment of hemophilia B
Factor IX replacement in surgery and prophylaxis
Use of factor IX concentrates in active teenagers with hemophilia B
Long-term aspects of hemophilia B treatment
Long-term aspects of hemophilia B treatment
Product selection issues in the management of hemophilia B
Conclusion
List of contributors